Hans van Houte
2023
In 2023, Hans van Houte earned a total compensation of $1.6M as Chief Financial Officer at Nurix Therapeutics, a 63% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $193,640 |
|---|---|
| Option Awards | $670,084 |
| Salary | $482,925 |
| Stock Awards | $259,920 |
| Other | $5,418 |
| Total | $1,611,987 |
van Houte received $670.1K in option awards, accounting for 42% of the total pay in 2023.
van Houte also received $193.6K in non-equity incentive plan, $482.9K in salary, $259.9K in stock awards and $5.4K in other compensation.
Rankings
In 2023, Hans van Houte's compensation ranked 728th out of 2,949 executives tracked by ExecPay. In other words, van Houte earned more than 75.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 728 out of 2,949 | 75th |
Division Manufacturing | 417 out of 1,622 | 74th |
Major group Chemicals And Allied Products | 282 out of 904 | 69th |
Industry group Drugs | 276 out of 867 | 68th |
Industry Pharmaceutical Preparations | 182 out of 625 | 71st |
Source: SEC filing on March 27, 2024.
van Houte's colleagues
We found two more compensation records of executives who worked with Hans van Houte at Nurix Therapeutics in 2023.